Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma

Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of upfront ASCT are still deba...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2019-12, Vol.54 (12), p.2051-2059
Main Authors: Lee, Yoo Jin, Moon, Joon Ho, Sohn, Sang Kyun, Kim, Seok Jin, Jung, Sung-Hoon, Lee, Je-Jung, Jo, Jae-Cheol, Shin, Ho-Jin, Lee, Won Sik, Lee, Ji Hyun, Bae, Sung Hwa, Kim, Min Kyoung, Lee, Ho Sup, Kim, Kihyun, Min, Chang-Ki
Format: Article
Language:English
Subjects:
631/67/1059/99
692/699/1541/1990/804
Adult
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Bortezomib
Bortezomib - pharmacology
Bortezomib - therapeutic use
Care and treatment
Cell Biology
Comparative analysis
Dexamethasone
Dexamethasone - pharmacology
Dexamethasone - therapeutic use
Female
Hematology
Humans
Induction Chemotherapy - methods
Induction therapy
Internal Medicine
Male
Medical colleges
Medicine & Public Health
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multivariate analysis
Patients
Public Health
Stem cell transplantation
Stem Cells
Steroids
Targeted cancer therapy
Thalidomide
Thalidomide - pharmacology
Thalidomide - therapeutic use
Therapy
Transplantation
β2 Microglobulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bortezomib/thalidomide/dexamethasone (VTD) induction therapy followed by autologous stem cell transplantation (ASCT) is one of the standard therapies for newly diagnosed multiple myeloma (NDMM). However, the appropriate depth of response to induction therapy and timing of upfront ASCT are still debated. We investigated if two additional cycles of VTD (VTD6) improved the responses and progression-free survival (PFS) compared with four cycles of VTD (VTD4). We retrospectively reviewed outcomes of 190 NDMM patients treated with at least four cycles of VTD followed by ASCT between September 2014 and August 2017 [VTD4, n  = 129 (67.9%); VTD6, n  = 61 (32.1%)]. The VTD6 group had a higher pre-ASCT complete response (CR) rate than the VTD4 group (31.1% versus 10.1%, P  
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-019-0629-7